BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Toxicities continue to pose the most significant challenge in 
 the progression of antibody-drug conjugates to the clinic\, and with incr
 easing companies entering into the ADC space and tackling toxicity\, ther
 e is ever-increasing target and indication-competition. Considering the s
 ignificant clinical setbacks witnessed in 2023\, the demand to better und
 erstand the translatability of toxicities and develop more tolerable ADCs
  for achieving future clinical triumphs only grows stronger.\n\nBy addres
 sing translational challenges and tackling off-target toxicities\, the 2n
 d ADC Toxicity Summit is returning at an imperative time to allow you to 
 prevent\, predict and mitigate toxicities in order to design and develop 
 ADCs with a wider therapeutic index and progress them to the clinic.\n\nJ
 oin 80+ of your colleagues from Pfizer\, Merck\, ImmunoGen\, Mersana\, Da
 iichi Sankyo\, AbbVie and more\, to discuss shared challenges with ADC to
 xicities from in vitro all the way to the clinic. Hear from experts in to
 xicology and translational sciences as they disclose never-heard before t
 oxicity data\, share insights into optimal in vivo models for predictabil
 ity\, investigate the use of biomarkers for patient specific ADC prescrip
 tion and introduce innovative strategies to transform the ADC landscape t
 o increase therapeutic index.\n\nJoin us in uniting the leading minds in 
 ADC toxicology\, offering actionable insights to unlock the full potentia
 l of predicting and mitigating toxicities in ADC development and addressi
 ng unmet needs head-on across three days of highly focused content - Don'
 t miss out!\n\nURLs:Website:&nbsp\;https://go.evvnt.com/2381308-0?pid=185
 Tickets:&nbsp\;https://go.evvnt.com/2381308-2?pid=185Brochure:&nbsp\;http
 s://go.evvnt.com/2381308-3?pid=185\n\nPrices:FULL PACKAGE: Conference + W
 orkshop Day - Drug Developer: USD 4197.00\,Conference Only - Drug Develop
 er: USD 2999.00\,FULL PACKAGE: Conference + Workshop Day - Solution Provi
 der: USD 5097.00\,Conference Only - Solution Provider: USD 3699.00\n\nSpe
 akers:&nbsp\;Ali Warbington\, Director\, Toxicology\, ImmunoGen\, Arnima 
 Bisht\, Senior Director\, Oxford BioTherapeutics\, Christian Marsolais\, 
 Senior Vice-President and Chief Medical Officer\, Theratechnologies Inc.\
 , Doo Young Jung\, CEO\, pinotbio\, Grace Lytle\, Executive Ocular Medica
 l Director\, ImmunoGen\, Jacqueline Kinyamu-Akunda\, Global Head of ADC D
 iscovery and Development\, Johnson and Johnson\, Josée Hue-Perron\, Assoc
 iate Principal Scientist in Preclinical Safety\, Debiopharm\, Jutta Decke
 rt\, Vice President\, Research and Development\, Iksuda Therapeutics\, Kr
 istin Decker\, Associate Director Pharmacology and Toxicology\, Heidelber
 g Pharma\, Laurie Tatalick\, Consultant\, Laurie Tatalick Consulting\, Ma
 rini Thian\, Senior Scientist\, Takeda\, Melissa Schutten\, Senior Direct
 or\, Pathology\, Pfizer\, Michael Oropallo\, Principal Scientist\, Merck 
 and Co\, Natalie Keirstead\, Senior Vice President - Nonclinical Developm
 ent\, Mersana Therapeutics\, Paul Jaminet\, President\, Angiex\, Philip H
 uxley\, Vice President\, Oncology\, Bicycle Therapeutics\, Piper Treuting
 \, Director - Translational Sciences and Pathology\, Pfizer\, Ronnie Yeag
 er\, Project Director\, Emerging Therapeutic Platforms\, Abbvie\, Werner 
 Rubas\, Vice President - Preclinical Development\, Sutro Biopharma\, Zent
 a Tsuchihashi\, Senior Director - Translational Science and Oncology\, Da
 iichi Sankyo\, Inc.\n\nCategory:&nbsp\;Conferences | Science\, Health and
  Medicine | Pharmaceuticals | Drug Discovery\n\nDate and Time:&nbsp\;23rd
  July 2024 at 9:00 am to 25th July 2024 at 5:00 pm\n
DTEND:20240725T170000
DTSTAMP:20260512T223119Z
DTSTART:20240723T090000
LOCATION:Hilton Boston Back Bay\, 40\, Dalton Street\, Boston\, Massachuse
 tts\, 02115\,
SEQUENCE:0
SUMMARY:Toxicities continue to pose the most significant challenge in the 
 progression of antibody-drug conjugates to the clinic\, and with increasi
 ng compan...
UID:1995c9c7-2476-4884-94c0-436d0ebf9ea0
END:VEVENT
END:VCALENDAR